- Home
- FCFS vs HALO Comparison
FCFS vs HALO Comparison
Compare FCFS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FCFS | HALO |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 8.8B |
| IPO Year | 1996 | 2001 |
Fundamental Metrics
Financial Performance| Metric | FCFS | HALO |
|---|---|---|
| Price | $192.48 | $65.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $179.33 | $78.18 |
| AVG Volume (30 Days) | 237.2K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | ★ 29.49 | N/A |
| EPS | ★ 7.42 | 2.56 |
| Revenue | ★ $3,661,043,000.00 | $151,862,000.00 |
| Revenue This Year | $16.17 | $28.24 |
| Revenue Next Year | N/A | $12.79 |
| P/E Ratio | $25.75 | ★ $25.41 |
| Revenue Growth | ★ 8.04 | N/A |
| 52 Week Low | $114.50 | $47.50 |
| 52 Week High | $199.60 | $82.22 |
Technical Indicators
Market Signals| Indicator | FCFS | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 34.25 |
| Support Level | $178.78 | $63.85 |
| Resistance Level | $199.60 | $65.40 |
| Average True Range (ATR) | 6.21 | 1.85 |
| MACD | -0.81 | -0.52 |
| Stochastic Oscillator | 59.83 | 19.49 |
Price Performance
Historical ComparisonAbout FCFS FirstCash Holdings Inc.
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.